Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.

@article{Roy2006SurvivalAF,
  title={Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.},
  author={Lydia Roy and Jo{\"e}lle Guilhot and Tillmann Krahnke and Agn{\'e}s Guerci-Bresler and Brian J. Druker and Richard A Larson and Steve O'Brien and Charlene So and Giorgio Massimini and François Guilhot},
  journal={Blood},
  year={2006},
  volume={108 5},
  pages={1478-84}
}
In the multinational IRIS study comparing imatinib with interferon plus cytarabine (IFN/Ara-C) in patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CP CML), imatinib demonstrated significantly higher rates of complete cytogenetic responses (CCyRs) and improved progression-free survival (PFS). However, because of a high early crossover rate to imatinib, survival benefit was not assessable. Here, we report the result of a study comparing long-term outcome of patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 79 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Retrospective comparison of imatinib versus interferon plus cytarabine (IFN/Ara-c) for chronic myelogenous leukemia (CML) patients in chronic phase (CP) [abstract

  • F Guilhot, L Roy, J Guilhot
  • Blood. 2005;106(suppl 1):165a
  • 2005
1 Excerpt

The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon

  • J Hasford, M Pfirmann, P Shepherd
  • Haematologica
  • 2005
2 Excerpts

Similar Papers

Loading similar papers…